Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M286,135Revenue $M71,312Net Margin (%)19.4Z-Score5.3
Enterprise Value $M274,035EPS $4.8Operating Margin %25.8F-Score7
P/E(ttm))19.2Cash Flow Per Share $6.2Pre-tax Margin (%)21.7Higher ROA y-yY
Price/Book3.810-y EBITDA Growth Rate %3.5Quick Ratio2.1Cash flow > EarningsY
Price/Sales4.15-y EBITDA Growth Rate %-0.9Current Ratio2.4Lower Leverage y-yN
Price/Cash Flow11.3y-y EBITDA Growth Rate %19.6ROA % (ttm)10.4Higher Current Ratio y-yY
Dividend Yield %2.6Insider Buy (3m)0ROE % (ttm)18.7Less Shares Outstanding y-yN
Payout Ratio %51.0Shares Outstanding M2,829ROI % (ttm)15.4Gross Margin Increase y-yY

Gurus Latest Trades with JNJ

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
JNJYacktman Focused Fund 2014-06-30 Reduce-0.51%$96.54 - $105.76
($101.02)
$ 102.31%Reduce -13.16%3,300,000
JNJRay Dalio 2014-03-31 Add0.12%$86.62 - $97.44
($92.6)
$ 102.310%Add 132.34%262,993
JNJGeorge Soros 2014-03-31 Buy 0.1%$86.62 - $97.44
($92.6)
$ 102.310%New holding, 102500 sh.102,500
JNJJoel Greenblatt 2014-03-31 Buy 0.01%$86.62 - $97.44
($92.6)
$ 102.310%New holding, 7496 sh.7,496
JNJJohn Hussman 2014-03-31 Reduce-0.65%$86.62 - $97.44
($92.63)
$ 102.310%Reduce -97.42%2,650
JNJPRIMECAP Management 2014-03-31 Reduce-0.15%$86.62 - $97.44
($92.6)
$ 102.310%Reduce -10.14%12,300,986
JNJRay Dalio 2013-12-31 Add0.06%$85.61 - $95.63
($92.24)
$ 102.311%Add 314.73%113,193
JNJPrem Watsa 2013-12-31 Reduce-15.54%$85.61 - $95.63
($92.24)
$ 102.311%Reduce -97.12%84,700
JNJGeorge Soros 2013-12-31 Sold Out -1.2%$85.61 - $95.63
($92.24)
$ 102.311%Sold Out0
JNJVanguard Health Care Fund 2013-12-31 Sold Out -0.85%$85.61 - $95.63
($92.24)
$ 102.311%Sold Out0
JNJJohn Hussman 2013-12-31 Reduce-0.48%$85.61 - $95.63
($92.24)
$ 102.311%Reduce -49.35%102,650
JNJJoel Greenblatt 2013-12-31 Sold Out -0.09%$85.61 - $95.63
($92.24)
$ 102.311%Sold Out0
JNJJoel Greenblatt 2013-09-30 Buy 0.09%$86.17 - $94.39
($89.81)
$ 102.314%New holding, 32599 sh.32,599
JNJRuane Cunniff 2013-09-30 Add0.03%$86.17 - $94.39
($89.81)
$ 102.314%Add 420.69%74,495
JNJRay Dalio 2013-09-30 Buy 0.02%$86.17 - $94.39
($89.81)
$ 102.314%New holding, 27293 sh.27,293
JNJPrem Watsa 2013-09-30 Reduce-10.26%$86.17 - $94.39
($89.81)
$ 102.314%Reduce -50.27%2,941,741
JNJGeorge Soros 2013-09-30 Reduce-1.2%$86.17 - $94.39
($89.81)
$ 102.314%Reduce -50%1,267,000
JNJJohn Hussman 2013-09-30 Reduce-0.2%$86.17 - $94.39
($89.81)
$ 102.314%Reduce -19.79%202,650
JNJVanguard Health Care Fund 2013-09-30 Reduce-0.11%$86.17 - $94.39
($89.81)
$ 102.314%Reduce -11.42%2,897,600
JNJJohn Hussman 2013-06-30 Add0.98%$81.11 - $88.59
($84.86)
$ 102.321%Add 9433.96%252,650
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

JNJ is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
JNJ Yacktman Fund 2014-06-304,050,0000.143.6
JNJ Yacktman Focused Fund 2014-06-303,300,0000.123.5-13.16%
JNJ George Soros 2014-03-31102,50000.1New Buy
JNJ Joel Greenblatt 2014-03-317,49600.01New Buy
JNJ Ray Dalio 2014-03-31262,9930.010.21+132.34%
JNJ Ruane Cunniff 2014-03-3175,79400.04+2.29%
JNJ Jean-Marie Eveillard 2014-03-311,617,5670.060.42+0.64%
JNJ Prem Watsa 2014-03-3184,70000.58
JNJ Michael Price 2014-03-3135,00000.42
JNJ Warren Buffett 2014-03-31327,1000.010.03
JNJ Dodge & Cox 2014-03-3138,62500
JNJ Richard Perry 2014-03-31342,2770.010.94
JNJ Donald Yacktman 2014-03-319,572,8500.343.9-0.39%
JNJ Tweedy Browne 2014-03-314,269,2060.159.7-0.85%
JNJ Tom Gayner 2014-03-31574,2000.021.7-1.1%
JNJ James Barrow 2014-03-3116,953,0290.62.4-2.18%
JNJ Mario Gabelli 2014-03-31395,0610.010.21-4.06%
JNJ PRIMECAP Management 2014-03-3112,300,9860.431.4-10.14%
JNJ John Hussman 2014-03-312,65000.02-97.42%
JNJ Meridian Funds 2013-06-307,88500.03
Premium Most recent portfolio changes are included for Premium Members only!


JNJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
COSGROVE STEPHEN JCorporate Controller 2014-05-05Sell22,000$100.052.25view
Fasolo PeterVP, Global Human Resources 2014-03-14Sell6,824$93.159.82view
COSGROVE STEPHEN JCorporate Controller 2013-08-14Sell17,200$91.3911.94view
Ullmann Michael HVP, General Counsel 2013-08-05Sell16,140$93.689.2view
Stoffels PaulusChief Scientific Officer 2013-07-25Sell45,440$92.410.71view
Caruso Dominic JVP, Finance; CFO 2013-07-18Sell30,000$90.3113.28view
CULLEN JAMESDirector 2013-05-07Sell4,929$85.419.79view
LINDQUIST SUSAN LDirector 2012-12-07Sell7,600$70.0246.1view
CULLEN JAMESDirector 2012-11-12Sell13,900$69.746.77view
Caruso Dominic JCFO 2012-10-19Sell20,400$71.9542.18view

Press Releases about JNJ :

    Quarterly/Annual Reports about JNJ:

    News about JNJ:

    Articles On GuruFocus.com
    Limiting Risk: A Little Exposure To High Yield Goes A Long Way Jul 29 2014 
    What’s the Right PE Ratio? Jul 29 2014 
    Is Ken Fisher a Dividend Growth Investor? Jul 27 2014 
    Just Post-It: 3M Is a Good Bet for Your Portfolio Today Jul 24 2014 
    3 Dividend Stocks For Retirement Jul 23 2014 
    Top Five Mega-Cap Stocks That Gurus Like Jun 25 2014 
    Pharma Sector Stocks To Consider For Sustained Returns Jun 25 2014 
    Running an Offense or Defense? Jun 22 2014 
    The Split That Makes Me Want More Jun 20 2014 
    Investors May Add Johnson & Johnson to Their Portfolio Jun 16 2014 


    More From Other Websites
    [$$] Johnson & Johnson to Call for Return of Hysterectomy Device Jul 30 2014
    Top defensive picks in offensive sectors Jul 30 2014
    IBM Adds Johnson & Johnson CEO, Retired Shell Chief to Board Jul 29 2014
    U.S. Senate panel to look into price setting for contact lenses Jul 29 2014
    Omnicom Tops Forecasts Despite Failed Publicis Merger Jul 28 2014
    Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval Jul 28 2014
    What Makes Johnson & Johnson a Healthy Dividend Investment Jul 28 2014
    Dispute Between Medical Giants Johnson & Johnson and Boston Scientific Moving to Trial Jul 27 2014
    Zacks Investment Ideas feature highlights: Wal-Mart, Johnson and Johnson and Hewlett-Packard Jul 25 2014
    Europe backs new leukaemia drugs from J&J and Gilead Jul 25 2014
    Europe backs new leukaemia drugs from J&J and Gilead Jul 25 2014
    Johnson & Johnson partners with Organovo to consider 3D-printing living tissue Jul 24 2014
    JNJ: Another Win Added To The Earnings Season Jul 24 2014
    [video] Cramer's Mad Dash: GILD bounces Jul 24 2014
    More Questions Raised About Boehringer Ingelheim's Pradaxa Jul 23 2014
    Alexion, 3 Other Top Biotechs Reporting Earnings Jul 22 2014
    Why Johnson & Johnson (JNJ) Stock Is Up Today Jul 22 2014

    Add Notes, Comments or Ask Questions

    User Comments

    Gurufocus
    ReplyGurufocus - 9 months ago
    test
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide